Focusing on in-vitro diagnostics and being China’s POCT leader, Wondfo always strives to make breakthrough innovations to push the boundaries of technologies in this area.
Our R&D Srength
Our annual investment to R&D accounts for over 10% of sales revenue, 1.6 times larger that the industry average, and continues to grow year on year.
Currently, we have an R&D team of 532 employees professional in biochemistry, clinical medicine, microelectronics technology, and have built R&D centers in China (Guangzhou, Hangzhou), and the United States (San Diego).
Besides, we build laboratories in cooperation with a number of key universities, further strengthing our R&D capacity.
Our R&D Achievements
With stronger R&D capacity and relentless efforts to R&D, Wondfo has already got 226 authorized patents, 172 trade marks registered in China, 113 registede in overseas countries, 189 NMPA, 162 CE, 69 510(K) clearances, 3 Health Canada MDLL.
We will continue to deliver more comprehensive and effective solutions in diagnostic testing, and to provide health care facilities worldwide with high-quality, safe, and more cost-effective products that help improve diagnostics efficiency and the effective of treatment monitoring.
It’s our passion and commitment to save lives and promote public health with top-of-the-line products and services.